Immunocore (IMCR)
(Delayed Data from NSDQ)
$38.29 USD
+0.83 (2.22%)
Updated Jul 9, 2024 04:00 PM ET
3-Hold of 5 3
F Value B Growth F Momentum D VGM
Brokerage Reports
Immunocore Holdings PLC Sponsored ADR [IMCR]
Reports for Purchase
Showing records 21 - 32 ( 32 total )
Company: Immunocore Holdings PLC Sponsored ADR
Industry: Medical - Biomedical and Genetics
Company: Immunocore Holdings PLC Sponsored ADR
Industry: Medical - Biomedical and Genetics
KIMMTRAK Exceeding Launch Expectations; Pipeline Programs on Track; Upping Price Target to $90; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Immunocore Holdings PLC Sponsored ADR
Industry: Medical - Biomedical and Genetics
ESMO Presentation Supports Bullish Thesis on IMC-F106C Targeting PRAME; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Immunocore Holdings PLC Sponsored ADR
Industry: Medical - Biomedical and Genetics
Positive Updates From ESMO on Lead Compounds KIMMTRAK and IMC-F106C; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Immunocore Holdings PLC Sponsored ADR
Industry: Medical - Biomedical and Genetics
2Q22 Results; KIMMTRAK Revenues Beat Expectations; Pipeline Progressing; Significant Datasets Expected 2H22
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Immunocore Holdings PLC Sponsored ADR
Industry: Medical - Biomedical and Genetics
Presents Initial Compelling Data From CHB Program at EASL Demonstrating Target Engagement
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Immunocore Holdings PLC Sponsored ADR
Industry: Medical - Biomedical and Genetics
Compelling Melanoma Data Presented at ASCO, Sanofi Collaboration Supports Bull Thesis
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Immunocore Holdings PLC Sponsored ADR
Industry: Medical - Biomedical and Genetics
1Q22 Results; KIMMTRAK Launch Off to Strong Start;PRAME and MAGE-A4 Data Readouts Expected 2H22
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Immunocore Holdings PLC Sponsored ADR
Industry: Medical - Biomedical and Genetics
EC Approves KIMMTRAK For the Treatment of Unresectable or Metastatic Uveal Melanoma; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Immunocore Holdings PLC Sponsored ADR
Industry: Medical - Biomedical and Genetics
4Q21 Results; KIMMTRAK Commericalization on Track, Pipeline Progressing in Catalyst-Rich 2022
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P